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Objective: To determine the efﬁ  cacy of cholinesterase inhibitors (ChEIs) in improving the 
behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s 
disease (AD).
Data sources: We searched MEDLINE, Cochrane Registry, and the Cumulative Index to 
Nursing and Allied Health Literature (CINAHL) from 1966 to 2007. We limited our search to 
English Language, full text, published articles and human studies.
Data extraction: We included randomized, double-blind, placebo-controlled trials evaluating 
the efﬁ  cacy of donepezil, rivastigmine, or galantamine in managing BPSD displayed by AD 
patients. Using the United States Preventive Services Task Force (USPSTF) guidelines, 
we critically appraised all studies and included only those with an attrition rate of less than 
40%, concealed measurement of the outcomes, and intention to treat analysis of the collected 
data. All data were imputed into pre-deﬁ  ned evidence based tables and were pooled using the 
Review Manager 4.2.1 software for data synthesis.
Results: We found 12 studies that met our inclusion criteria but only nine of them provided 
sufﬁ  cient data for the meta-analysis. Among patients with mild to severe AD and in comparison 
to placebo, ChEIs as a class had a beneﬁ  cial effects on reducing BPSD with a standard mean 
difference (SMD) of −0.10 (95% conﬁ  dence interval [CI]; −0.18, −0.01) and a weighted 
mean difference (WMD) of −1.38 neuropsychiatry inventory point (95% CI; −2.30, −0.46). 
In studies with mild AD patients, the WMD was −1.92 (95% CI; −3.18, −0.66); and in studies 
with severe AD patients, the WMD was −0.06 (95% CI; −2.12, +0.57).
Conclusion: Cholinesterase inhibitors lead to a statistical signiﬁ  cant reduction in BPSD among 
patients with AD, yet the clinical relevance of this effect remains unclear.
Keywords: Alzheimer’s disease, dementia, cholinesterase inhibitors, behavioral and 
psychological symptoms
Introduction
The noncognitive behavioral and psychological symptoms of dementia (BPSD) 
displayed by patients suffering from Alzheimer disease (AD) include a heterogeneous 
spectrum of psychological reactions, psychiatric symptoms, and behaviors (Finkel 
et al 2000). More than 90% of AD patients will experience at least one BPSD at some 
point during the course of their illness (Tariot and Blazina 1994; Haupt et al 2000; 
Lyketsos et al 2000). A community-based epidemiological study found that 61% of 
AD patients exhibited one or more BPSD in the past month and 61% of those with 
no baseline BPSD developed at least one symptom within 18 months (Lyketsos et al 
2000; Steinberg et al 2003). In a nursing home study a baseline prevalence of 76%, a 
two-year prevalence of 82%, and an annual incidence of 64% was detected (Ballard 
et al 2001).Clinical Interventions in Aging 2008:3(4) 720
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BPSD are a major problem for patients and their caregivers. 
They are considered one of the strongest predictors for 
institutionalization of demented patients (Colerick and George 
1986; Steele et al 1990; O’Donnell et al 1992; Haupt and Kurz 
1993; Teresi and Weiner 1993; Swearer 1994); a prominent 
risk factor for caregiver burden and psychological morbidity 
(Kinney and Stephens 1989; Hamel et al 1990; Haupt and Kurz 
1993; Morris et al 1996); a signiﬁ  cant obstacle in achieving 
adequate medical management for other health conditions 
(Cohen-Mansﬁ  eld 1995; Brodaty et al 2001); and a common 
cause of stress leading to staff burnout and subsequent turnover 
in institutional settings (Maslach and Jackson 1981).
The traditional pharmacological management of BPSD 
has signiﬁ  cant morbidity including extrapyramidal signs and 
symptoms, gait abnormalities, sedation, an increased risk of 
falls and fractures, incidence of delirium, cerebrovascular 
events, and death (Cummings 2000a; Cummings et al 2000, 
2001; Boustani et al 2002). An agent speciﬁ  c for AD that can 
treat BPSD with fewer side effects is highly desirable. Currently 
ChEIs are the standard of care for the treatment of cognitive 
deﬁ  cit in patients with AD (Doody et al 2001; Boustani et al 
2002). Compared to alternatives, they are considered to have a 
more acceptable side effect proﬁ  le (Boustani et al 2002). Over 
the past decade, their potential role as psychotropic agents has 
been investigated in a variety of basic and clinical studies, which 
have suggested that the central cholinergic deﬁ  cit associated 
with AD may be causative for the cognitive deterioration and 
the neuropsychiatric manifestations of AD (Kaufer et al 1998; 
Cummings 2000a, 2000b; Cummings et al 2001; Chung and 
Cummings 2000). Previously, evaluating the use of ChEIs in 
managing BPSD has been reported in a meta-analysis by Trinh 
and colleagues (2003) which included published trials of ChEIs 
up to 2001. Trinh included patients with mild-moderate AD 
only and included studies which used metrifonate, which is no 
longer available for the treatment of AD. However, since the 
publication of Trinh meta-analysis, numerous new trials have 
been published that investigated further the role of ChEIs as a 
psychotherapeutic agent in AD. The aim of our study was to 
systematically review the available literature and examine the 
therapeutic role of the currently available ChEIs in decreasing 
the burden of BPSD among patients with any stage of AD 
living in any clinical setting.
Methods
Search strategies
We searched MEDLINE from 1966 to 2007, Cochrane 
Collaboration Registry for Randomized Controlled 
Trials (RCT) from 1966 to 2007 and CINAHL from 
1982 to 2007, using the following search terms: Alzheimer’s 
disease, dementia, donepezil, rivastigmine, galantamine, 
cholinesterase inhibitors and behavioral and psychological 
symptoms. We limited our search to the English language, 
full text, published articles and human studies. We also 
retrieved relevant references of included studies for 
our search.
Selection criteria
The main goal of our systematic evidence review (SER) was to 
evaluate the efﬁ  cacy of the currently available ChEIs in treating 
BPSD in patients with AD. Thus, we included only RCTs that 
evaluated the efﬁ  cacy of any of the three FDA-approved and 
commonly used ChEIs (donepezil, rivastigmine, galantamine). 
We also included only studies that measured the BPSD with 
the Neuropsychiatric Inventory (NPI) among patients with 
any stage of AD living in any clinical setting. We selected 
NPI as the main outcome measure because it is considered by 
many investigators as the standard method to measure BPSD. 
The NPI is an informant-based structured interview with 
acceptable psychometric properties (Cummings et al 1994; 
Cummings and Kaufer 1996; Wood et al 2000; Schneider et al 
2001). Higher scores indicate higher frequency and severity of 
BPSD and a positive change from baseline reﬂ  ects worsening 
symptoms (Cummings et al 1994). We excluded pre and post 
studies and randomized controlled trials involving patients 
other than AD. Studies which were not placebo-controlled 
were also excluded from our SER.
Critical appraisal
Using the USPSTF critical appraisal method for quality 
assessment, we critically appraised the studies and included 
those with an attrition rate of less than 40%, a concealed 
measurement of the outcomes, and intention to treat analysis 
of the collected data.
Data abstraction
Three reviewers (AA, MB, NC) independently searched 
for the articles and abstracted data from each study that 
met our inclusion criteria into predeﬁ  ned evidence tables, 
that included: citation, total number of randomized 
patients, baseline demographic data (age, gender, educational 
level), mean Mini-Mental Status Examination score 
(MMSE), setting, duration of studies, drug used in studies, 
attrition rate, mean total NPI score, mean change from 
baseline of the total NPI score for both the treatment and 
placebo groups, and the level of signiﬁ  cance for the mean 
difference in NPI between the two groups.Clinical Interventions in Aging 2008:3(4) 721
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Quantitative data synthesis
We used Review Manager Software Version 4.2.1 (http://
www.cc-ims.net/RevMan; Plone Foundation, Houston, TX, 
USA) to calculate the effect size and conﬁ  dence interval (CI) 
of each individual study and the combined results. The effect 
size is the difference in the change of the total NPI score 
from baseline between the treatment and the placebo groups 
divided by the pooled standard deviation. In addition, we were 
also interested in identifying any potential confounder for the 
effect of ChEIs on BPSD such as disease stage and speciﬁ  c 
drug. Thus, we conducted a series of sensitivity analyses 
that combined data from the studies using similar inclusion 
criteria and interventions. Authors were also contacted for the 
data not reported or missing in the studies. After testing the 
heterogeneity of included trials, we primarily used a random 
effect model to combine the results of included studies. 
Other factors which were considered when carrying out the 
meta- analysis were sources of variation, such as sample sizes, 
dosing regimens, differences between treatment durations and 
routes of administration. Confounding variables would be 
MMSE scores or stage of symptom and age of the patients. 
Variations such as these would impact effect sizes, but as long 
as these effect sizes are in the same direction, whether negative 
or positive, a reliable effect would be evident.
Results
Review ﬂ  ow
Our search strategies yield a total of 105 potentially relevant 
RCTs for retrieval. sixteen studies were excluded as they 
were not placebo-controlled trials and 27 studies were further 
excluded as they were open label, subgroup analyses or 
duplicate studies. Out of remaining 62 studies, 50 studies 
were excluded as they failed to meet the inclusion criteria. 
Finally, 12 randomized controlled trials (RCTs) met the 
inclusion criteria for our SER (see Tables 1 and 2) and 
only nine studies provided complete data to conduct the 
meta-analysis.
Study characteristics
As demonstrated in Tables 1 and 2, the included studies 
were conducted among a heterogeneous group of partici-
pants with mild to severe cognitive deﬁ  cits with a mean 
MMSE score ranging from 6.1 to 21. The mean differ-
ence of the primary outcome measure was not reported 
in three studies, which were therefore excluded from the 
meta-analysis. Five studies were conducted in outpatient 
settings, two in nursing homes, four in community and 
residential settings together, and one study did not report 
the clinical setting. Nine studies compared donepezil, two 
compared galantamine and one compared rivastigmine 
with placebos. The length of the studies varied from 3 to 
12 months. The target dose of donepezil was 10 mg per 
day; that of galantamine varied from 16 to 24 mg daily; 
and rivastigmine was administered as either a capsule or a 
skin patch with target doses of 3–12 mg and 20 cm2 patches 
per day, respectively.
The mean age of the participants ranged from 72.5 to 
85.7 years and the percentage of female participants ranged 
Table 1 Baseline variables of the included studies
Study N Mean age % Female Education 
level (years)
Mean MMSE Total NPI Score
Tariot et al 2000 978 76 64 NR 18 11.9 (10 items)
Feldman et al 2001 290 73.6 61 NR 12 19.55 (12 items)
Rockwood et al 2001 386 75 56.5 NR 20 9.20 (10 items)
Tariot et al 2001 208 85.7 82.5 NR 14 21.0 (12 items) 
NPI-NH
Winblad et al 2001 286 72.5 64 NR 19 13.05 (10 items)
Gauthier et al 2002 207 74.3 65 NR 13.7 17.3 (12 items)
Nunez et al 2003 202 – – – – –
AD2000 et al 2004 566 – 59 NR – –
Holmes et al 2004 96 80.9 60.5 NR 21 14.30 (10 items)
Winblad et al 2006 248 84.9 76.5 NR 6.1 19.30 (12 items)
Winblad et al 2007 1195 73.6 66.5 9.9 16.5 14.75 (12 items)
Howard et al 2007 259 84.6 84.5 NR 8.1 23.65 (12 items)
Abbreviations: N, total number of subjects included in the study; NPI, neuropsychiatric Inventory; NPI-NH, neuropsychiatric inventory-nursing home; NR, not reported.Clinical Interventions in Aging 2008:3(4) 722
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from 56.5% to 84.5%. Education level was reported in only 
one study and was 9.9 years. NPI was used as primary outcome 
measure in only two studies (Tariot et al 2001; Holmes et al 
2004) and the secondary outcome measure in nine studies for 
the assessment of BPSD. The mean baseline NPI score ranged 
from 9.20 to 23.65. Two different versions of the NPI (10-item 
scale with score ranges from 0 to 120 points versus 12-item 
scale with score ranges from 0 to 144) were used. Baseline 
total NPI score was higher in the ﬁ  ve studies that evaluated 
moderate to severe AD (15.1, 19.30, 19.55, 21.0 and 23.65) 
in comparison to the four studies which evaluated mild to 
moderate AD (9.2, 11.9, 13.05, 14.3).
Quantitative data analyses
The studies were not homogenous and therefore, we used the 
random effect model to combine their results and reported 
the standard mean difference (SMD). However, we have also 
reported the result from the ﬁ  xed effect model and reported 
the weighted mean difference (WMD) for comparison with 
other reported meta-analyses (See Figure 1).
Table 2 Evidence table for all included studies
Study Countries Setting Drug Length 
(months)
N Mean 
difference
Intervention 
attrition 
rate, %
Placebo 
attrition 
rate, %
Tariot et al 2000 USA Out-patient Galantamine 5 770 −2.10 SS 22 16
Feldman et al 
2001
Canada, 
Australia, 
France
Out-patient Donepezil 6 290 −5.65 SS 16 14
Rockwood et al 
2001
USA, 
Canada, 
Britain, 
South Africa, 
Australia, 
New Zealand
Out-patient Galantamine 3 386 −0.90 NS 33 10
Tariot et al 2001 USA Nursing 
homes
Donepezil 6 208 2.60 NS 18 26
Winblad et al 
2001
Northern 
European 
countries
Out-patient Donepezil 12 286 −1.13 NS 33 33
Gauthier et al 
2002
Canada, 
Australia, 
France, 
USA
Community/ 
Residential
Donepezil 6 207 NR 19 11
Nunez et al 
2003
Finland,
Hungary, 
Denmark.
NR Donepezil 6 202 NR NR NR
AD2000 et al 
2004
UK Community/ 
Residential
Donepezil 15 566 NR 11 5
Holmes et al 
2004
UK Out-patient Donepezil 6 96 −6.2 SS 15 18
Winblad et al 
2006
Sweden Nursing 
Homes
Donepezil 6 248 −1.70 NS 26 18
Winblad et al 
2007
Sweden, 
USA, 
Germany, 
Switzerland
Community/ 
Residential
Rivastigmine 
(20 cm-patch) 
(capsule)
6 1078 −0.60 NS
−0.50 NS
20
21
12
Howard et al 2007 United 
Kingdom
Residential/ 
Community
Donepezil 3 259 −0.22 NS 10 14
Abbreviations: MD, mean difference of change on total NPI score between placebo and treatment; NR, not reported; NS, not signiﬁ  cant; SS, statistically signiﬁ  cant.
Note: Negative values indicate greater improvement in symptoms in the active treatment group.Clinical Interventions in Aging 2008:3(4) 723
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Patients receiving ChEIs (donepezil, rivastigmine 
or galantamine) improved the total NPI score when 
compared to the placebo with a SMD between the 
two groups of −0.10 (95% CI: −0.18, −0.01) and a 
WMD of −1.38 (95% CI: −2.20, −0.46). Combining 
only the results of homogenous studies, for example, 
those conducted among patients with mild-moderate 
AD showed that the SMD between the two groups 
was −0.16 (95% CI: −0.28, −0.03) and the WMD was −1.92 
(95% CI: −3.18, −0.66) (see Figure 2).
When results of studies that included patients with 
moderate-severe AD were evaluated, the impact of ChEIs 
was not statistically signiﬁ  cant anymore with a SMD of −0.06 
(95% CI: −0.17, 0.05) and a WMD of −0.77(95% CI: −2.12, 
0.57) (see Figure 3).
Looking at the effect of each of the three ChEIs 
separately, we found that the SMD between galantamine 
and placebo (two studies) was −1.65 (95% CI: −3.10, −0.19), 
between donepezil and placebo (6 studies) was −1.76 
(95% CI: −3.37, −0.15) and between rivastigmine and placebo 
(one study) was −0.55 (95% CI: −2.31, 1.21).
Data on the individual domains of the NPI was not 
available to conduct a meta-analysis, but two studies 
(Feldman et al 2001; Tariot et al 2001) reported that 
donepezil signiﬁ  cantly improved depression/dysphoria and 
apathy, but only anxiety symptoms were improved in one 
trial and only agitation/aggression in the other.
Discussion
Clinically relevant change 
in BPSD as measured by NPI
Our meta-analysis found that in comparison to placebo, 3 to 
12 months’ treatment with ChEIs had positive effects on 
global BPSD scores with an effect size (SMD) of 0.10 and 
WMD of 1.38 NPI points. The challenge, however, is to 
determine the clinical signiﬁ  cance of this effect size and 
whether such an effect can be translated into reducing 
patients’ or caregivers’ burden. Various clinical investigators 
have used different total NPI points to determine the clinical 
meaning of NPI total change score. Kaufer and colleagues 
(1998) decided that a reduction or improvement of at least 
50% in the average baseline NPI scores, approximately 
nine points difference on the total NPI score, is considered 
a clinically relevant change. We compared our results to 
a similar study published by Trinh and colleagues (2003). 
This study evaluated the impact of ChEIs on behavioral 
symptoms in patients with mild-moderate AD. The authors Clinical Interventions in Aging 2008:3(4) 724
Campbell et al
F
a
v
o
r
s
 
t
r
e
a
t
m
e
n
t
F
a
v
o
r
s
 
c
o
n
t
r
o
l
R
e
v
i
e
w
:
C
o
m
p
a
r
i
s
o
n
:
O
u
t
c
o
m
e
:
S
t
u
d
y
o
r
 
s
u
b
-
c
a
t
e
g
o
r
y
N
N
T
r
e
a
t
m
e
n
t
M
e
a
n
 
(
S
D
)
C
o
n
t
r
o
l
M
e
a
n
 
(
S
D
)
W
M
D
 
(
f
i
x
e
d
)
W
M
D
 
(
f
i
x
e
d
)
9
5
%
 
C
I
9
5
%
 
C
I
%
W
e
i
g
h
t
0
1
 
C
h
E
I
s
 
v
s
 
P
l
a
c
e
b
o
 
(
s
t
u
d
i
e
s
 
w
i
t
h
 
m
i
l
d
 
t
o
 
m
o
d
e
r
a
t
e
 
A
D
 
a
n
d
 
u
s
e
d
 
1
0
 
i
t
e
m
 
N
P
I
 
s
c
o
r
e
)
:
 
 
 
T
a
r
i
o
t
 
2
0
0
0
R
o
c
k
w
o
o
d
 
2
0
0
1
W
i
n
b
l
a
d
 
2
0
0
1
H
o
l
m
e
s
 
2
0
0
4
S
u
b
t
o
t
a
l
 
(
9
5
%
 
C
I
)
T
e
s
t
 
f
o
r
 
h
e
t
e
r
o
g
e
n
e
i
t
y
:
 
C
h
i
z
 
=
 
4
.
5
2
,
 
d
f
 
=
 
3
 
(
P
 
=
 
0
.
2
1
)
,
 
I
z
 
=
 
3
3
.
7
%
T
e
s
t
 
f
o
r
 
o
v
e
r
a
l
l
 
e
f
f
e
c
t
:
 
Z
 
=
 
2
.
9
9
 
(
P
 
=
 
0
.
0
0
3
)
T
o
t
a
l
 
(
9
5
%
 
C
I
)
9
4
6
9
4
6
T
e
s
t
 
f
o
r
 
o
v
e
r
a
l
l
 
e
f
f
e
c
t
:
 
Z
 
=
 
2
.
9
9
 
(
P
 
=
 
0
.
0
0
3
)
T
e
s
t
 
f
o
r
 
h
e
t
e
r
o
g
e
n
e
i
t
y
:
 
C
h
i
z
 
=
 
4
.
5
2
,
 
d
f
 
=
 
3
 
(
P
 
=
 
0
.
2
1
)
,
 
I
z
 
=
 
3
3
.
7
%
5
8
0
5
5
1
3
8
1
2
5
2
6
2
5
0
8
2
6
1
1
3
6
4
1
5
8
0
–
0
.
1
0
 
(
1
3
.
3
6
)
2
.
0
0
 
(
1
1
.
8
4
)
–
1
.
9
2
 
[
–
3
.
1
8
,
 
–
0
.
6
6
]
–
1
.
9
2
 
[
–
3
.
1
8
,
 
–
0
.
6
6
]
–
6
.
2
0
 
[
–
1
0
.
6
7
,
 
–
1
.
7
3
]
–
1
.
1
3
 
[
–
4
.
2
1
,
 
1
.
9
5
]
–
0
.
9
0
 
[
–
3
.
2
6
,
 
1
.
4
6
]
–
2
.
1
0
 
[
–
3
.
9
5
,
 
–
0
.
2
5
]
0
.
5
0
 
(
1
1
.
2
9
)
3
.
3
0
 
(
1
3
.
3
6
)
1
.
7
2
 
(
1
2
.
2
3
)
–
0
.
4
0
 
(
1
0
.
6
6
)
–
2
.
9
0
 
(
8
.
9
6
)
0
.
5
9
 
(
1
3
.
7
6
)
0
–
5
5
1
0
–
1
0
1
0
0
.
0
0
1
0
0
.
0
0
1
6
.
7
5
4
6
.
7
8
2
8
.
5
0
7
.
9
7
0
2
-
 
T
h
e
 
E
f
f
i
c
a
c
y
 
o
f
 
C
h
E
I
s
 
(
D
o
n
e
p
e
z
i
l
,
R
i
v
a
s
t
i
g
m
i
n
e
 
a
n
d
 
G
a
l
a
n
t
a
m
i
n
e
)
 
o
n
 
B
P
S
D
 
i
n
 
 
A
D
.
 
A
 
M
e
t
a
-
A
n
a
l
y
s
i
s
.
0
2
 
C
h
E
I
s
 
v
s
 
P
l
a
c
e
b
o
 
(
F
i
x
e
d
 
E
f
f
e
c
t
 
M
o
d
e
l
)
0
1
 
C
h
a
n
g
e
 
i
n
 
T
o
t
a
l
 
N
P
I
 
s
c
o
r
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
:
F
i
g
u
r
e
 
2
 
T
h
e
 
e
f
f
e
c
t
s
 
o
f
 
C
h
E
I
s
 
o
n
 
B
P
S
D
 
a
m
o
n
g
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
m
i
l
d
 
t
o
 
m
o
d
e
r
a
t
e
 
A
D
.
F
i
g
u
r
e
 
3
 
T
h
e
 
e
f
f
e
c
t
s
 
o
f
 
C
h
E
I
s
 
o
n
 
B
P
S
D
 
a
m
o
n
g
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
m
o
d
e
r
a
t
e
 
t
o
 
s
e
v
e
r
e
 
A
D
.
F
a
v
o
r
s
 
t
r
e
a
t
m
e
n
t
F
a
v
o
r
s
 
c
o
n
t
r
o
l
R
e
v
i
e
w
:
C
o
m
p
a
r
i
s
o
n
:
O
u
t
c
o
m
e
:
S
t
u
d
y
o
r
 
s
u
b
-
c
a
t
e
g
o
r
y
N
N
T
r
e
a
t
m
e
n
t
M
e
a
n
 
(
S
D
)
C
o
n
t
r
o
l
M
e
a
n
 
(
S
D
)
W
M
D
 
(
f
i
x
e
d
)
W
M
D
 
(
f
i
x
e
d
)
9
5
%
 
C
I
9
5
%
 
C
I
%
W
e
i
g
h
t
T
a
r
i
o
t
 
2
0
0
1
F
e
l
d
m
e
n
 
2
0
0
1
S
u
b
t
o
t
a
l
 
(
9
5
%
 
C
I
)
T
e
s
t
 
f
o
r
 
h
e
t
e
r
o
g
e
n
e
i
t
y
:
 
C
h
i
z
 
=
 
7
.
8
3
,
 
d
f
 
=
 
5
 
(
P
 
=
 
0
.
1
7
)
,
 
I
z
 
=
 
3
6
.
2
%
T
e
s
t
 
f
o
r
 
o
v
e
r
a
l
l
 
e
f
f
e
c
t
:
 
Z
 
=
 
1
.
1
3
 
(
P
 
=
 
0
.
2
6
)
T
o
t
a
l
 
(
9
5
%
 
C
I
)
T
e
s
t
 
f
o
r
 
o
v
e
r
a
l
l
 
e
f
f
e
c
t
:
 
Z
 
=
 
1
.
1
3
 
(
P
 
=
 
0
.
2
6
)
T
e
s
t
 
f
o
r
 
h
e
t
e
r
o
g
e
n
e
i
t
y
:
 
C
h
i
z
 
=
 
7
.
8
3
,
 
d
f
 
=
 
5
 
(
P
 
=
 
0
.
1
7
)
,
 
I
z
 
=
 
3
6
.
2
%
0
–
5
5
1
0
–
1
0
0
2
-
 
T
h
e
 
E
f
f
i
c
a
c
y
 
o
f
 
C
h
E
I
s
 
(
D
o
n
e
p
e
z
i
l
,
R
i
v
a
s
t
i
g
m
i
n
e
 
a
n
d
 
G
a
l
a
n
t
a
m
i
n
e
)
 
o
n
 
B
P
S
D
 
i
n
 
 
A
D
.
 
A
 
M
e
t
a
-
A
n
a
l
y
s
i
s
.
0
9
 
C
h
E
I
s
 
v
s
 
P
l
a
c
e
b
o
 
(
F
i
x
e
d
 
E
f
f
e
c
t
 
M
o
d
e
l
)
:
0
1
 
C
h
a
n
g
e
 
i
n
 
T
o
t
a
l
 
N
P
I
 
s
c
o
r
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
:
1
0
1
0
9
7
2
9
7
2
2
5
3
2
6
3
1
0
4
1
0
3
1
2
8
1
2
1
1
0
1
0
9
7
1
2
0
1
2
6
1
0
5
2
8
1
2
8
1
W
i
n
b
l
a
d
 
2
0
0
6
W
i
n
b
l
a
d
 
2
0
0
7
W
i
n
b
l
a
d
 
2
0
0
7
a
H
o
w
a
r
d
 
2
0
0
7
0
1
 
C
h
E
I
s
 
v
s
 
P
l
a
c
e
b
o
 
(
s
t
u
d
i
e
s
 
w
i
t
h
 
m
o
d
e
r
a
t
e
 
t
o
 
s
e
v
e
r
e
 
A
D
 
a
n
d
 
u
s
e
d
 
1
2
 
i
t
e
m
 
N
P
I
 
s
c
o
r
e
)
:
–
0
.
7
7
 
[
–
2
.
1
2
,
 
0
.
5
7
]
–
0
.
7
7
 
[
–
2
.
1
2
,
 
0
.
5
7
]
–
5
.
6
5
 
[
–
1
0
.
0
5
,
 
–
1
.
2
5
]
2
.
6
0
 
[
–
1
.
3
7
,
 
6
.
5
7
]
–
1
.
7
0
 
[
–
5
.
5
6
,
 
2
.
1
6
]
–
0
.
2
2
 
[
–
4
.
7
3
,
 
4
.
2
9
]
–
0
.
6
0
 
[
–
3
.
0
5
,
 
1
.
8
5
]
–
0
.
5
0
 
[
–
3
.
0
3
,
 
2
.
0
3
]
1
0
0
.
0
0
1
0
0
.
0
0
2
8
.
2
2
9
.
3
1
1
1
.
4
5
1
2
.
0
8
8
.
8
5
3
0
.
0
9
3
.
7
8
 
(
1
6
.
7
0
)
–
1
.
7
0
 
(
1
5
.
7
0
)
–
1
.
7
0
 
(
1
5
.
7
0
)
–
3
.
8
0
 
(
1
5
.
2
0
)
–
4
.
6
5
 
(
1
7
.
7
6
)
–
2
.
3
0
 
(
1
4
.
5
0
)
3
.
5
6
 
(
1
5
.
9
0
)
–
2
.
3
0
 
(
1
3
.
4
0
)
–
2
.
2
0
 
(
1
4
.
1
0
)
–
2
.
1
0
 
(
1
5
.
8
0
)
1
.
0
0
 
(
1
7
.
5
2
)
–
4
.
9
0
 
(
1
4
.
7
0
)Clinical Interventions in Aging 2008:3(4) 725
The efﬁ  cacy of chEIs (donepezil, rivastigmine, and galantamine) on BPSD in Alzheimer’s disease
found a WMD in improvement in NPI scores between all 
ChEIs (including metrifonate) and placebo of 1.72 (95% CI: 
0.87–2.57). By comparison, our study found similar results 
as the Trinh study when results for a similar population were 
evaluated (WMD −1.92 for patients in a mild-moderate stage 
of dementia). However, our results suggest this difference in 
NPI scores does not extend to the moderate-severe population 
(WMD of −0.77 with 95% CI of −2.12 to +0.57). The efﬁ  -
cacy of ChEIs (galantamine and rivastigmine) on BPSD 
in other types of dementia such as vascular dementia and 
Lowy body dementia has been evaluated in two other studies 
(Erkinjuntti et al 2002; McKeith et al 2002). Both controlled 
trials had similar results as our study with a difference in 
mean change from baseline between treatment and placebo 
group of 2.3 points on the total NPI score for the vascular 
dementia trial (baseline total NPI score = 11.8) and 3.8 for 
trial including patients with Lewy body dementia (baseline 
total NPI score = 21.7). To further compare the clinical 
signiﬁ  cance of our meta-analysis, we looked at the results of 
trials that used the NPI to evaluate the efﬁ  cacy of an atypical 
antipsychotic (olanzapine) in reducing BPSD among AD 
nursing home residents who had clinically signiﬁ  cant levels 
of behavioral and psychological symptoms at baseline with 
a total NPI score of at least 44 points (Street et al 2000). 
In comparison to placebo, the mean decline from baseline 
in total NPI score was 8.3 points among patients taking 
olanzapine for six weeks (Street et al 2000). Although the 
ChEIs’ trials did not speciﬁ  cally enroll patients with baseline 
behavioral and psychological symptoms, the difference in 
the NPI changes from baseline between olanzapine and 
placebo was much higher than what we detected in our 
meta-analysis.
The natural history of the BPSD
Before evaluating the efﬁ  cacy of ChEIs on BPSD, one must 
examine their natural history as measured by a specific 
instrument such as the NPI. In a cross-sectional study, com-
munity dwelling elderly patients with dementia had a total NPI 
mean score of 7.11(SD = 10.9) as compared to 0.76 (SD = 2.89) 
points of those with no dementia. In addition, the total score 
increased as dementia-related disability worsened, individuals 
with mild dementia had a mean total score on the NPI of 
5.80 (SD = 12.5), those with moderate dementia had a mean 
score of 8.8 (SD = 11.10), and those with severe dementia 
had a mean score of 10.6 (SD = 17.0) (Lyketsos et al 2002). 
The mean total NPI score increased dramatically, ie, 36.4 
(SD = 24.5), among patients with moderate to severe dementia 
admitted to the hospital for the management of their disturbed 
behaviors (Iverson et al 2002). The prevalence data provide an 
idea of the total NPI score range but they do not explain the 
ﬂ  uctuating nature of BPSD. During any speciﬁ  ed period of time 
certain behaviors or symptoms will emerge, others will cease, 
some deteriorate, and others will improve (Levy et al 1996; 
Devanand et al 1997; Green et al 1999; Ballard et al 2001). 
This fluctuating pattern of BPSD must be accounted for 
when interpreting the efﬁ  cacy of certain interventions. We 
are unaware of any study that tried to determine whether this 
ﬂ  uctuating pattern occurred on daily, weekly, monthly, or 
yearly basis.
Limitations
Our study has some limitations. First, we restricted our 
review to BPSD measured by the NPI. We were concerned 
that including other measures would make it difﬁ  cult to 
interpret the data. Nevertheless, the NPI is considered the 
current standard instrument to evaluate BPSD. We previously 
reviewed all RCTs of ChEIs that evaluated the efﬁ  cacy of 
tacrine on BPSD and found similar results from trials using 
the Alzheimer’s Disease Assessment Scale-Noncognitive 
symptoms (ADAS-noncog) (Cummings et al 2001). Sec-
ondly, we did not include individual domains of the NPI in 
our analysis, which may have truncated our ﬁ  ndings. There is 
lack of published data on each of these 12 domains, although 
two included trials (Tariot et al 2000; Feldman et al 2001) 
reported the effect on individual domains but did not pro-
duce data that could be combined for meta-analysis (Tariot 
et al 2000; Feldman et al 2001). As the effect of ChEIs are 
likely to be greater on some BPSD than others, we believe 
that evaluating the effects of cholinesterase inhibitors on 
individual domains may carry more clinical meaning than 
using the global scale which sums all the BPSD in one score. 
The third limitation is related to being unable to identify the 
difference in the proportion of responders between placebo 
and treatment groups. One trial (Tariot et al 2001) with NPI as 
the primary outcome reported the difference in the percentage 
of patients who had worsening symptoms on the agitation 
domain (placebo 32%, donepezil 24%), but it only stated 
that no signiﬁ  cant ﬁ  nding was detected in the other domains 
(Tariot et al 2001). We agree with Mulsant and colleagues 
(1997) in regard to the advantage of using comparisons based 
on the resolution of target BPSD domains or even the total 
score of NPI (categorical approach) rather than the use of 
an absolute or relative change in total score in interpreting 
the clinical value of certain interventions targeting BPSD. 
Finally, our review could not determine if the ChEI’s effects 
were due to stability of BPSD among the treatment group Clinical Interventions in Aging 2008:3(4) 726
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versus deterioration among the placebo group, or if their 
effects reﬂ  ected a true improvement in treatment groups.
Research need
Our review found a statistically signiﬁ  cant effect of ChEIs 
(donepezil, rivastigmine, and galantamine) on BPSD in AD 
patients. However, we could not interpret the clinical relevance 
of this ﬁ  nding. Given the heterogeneity of BPSD and the need 
to explore further the efﬁ  cacy of ChEIs in managing BPSD, 
we need to have a more clinically focused evaluation method. 
This method could be accomplished by either conducting a new 
clinical trial (a very expensive and ethically challenging method 
because ChEIs are considered to be the current standard of care 
in AD) or a retrospective post-hoc analysis of individual data 
from the 12 clinical trials that we included in our meta-analysis. 
The analytic framework for the suggested study would stratify 
the participants into two groups based on their baseline NPI 
total score: the prevention strata; which would include individu-
als with low NPI scores (20) and crisis intervention strata; 
which would include individuals with high NPI scores (20). 
Although the NPI would still be the main assessment tool, the 
trial would evaluate the impact of ChEIs using the individual 
domain scores for the NPI and a categorical approach to iden-
tify responders. The primary outcome would be the proportion 
of responders after 3 to 6 months. The responders would be 
deﬁ  ned differently between the two strata: in the prevention 
strata, the responders would include any individual with at least 
a stable NPI domain score at the end of the study, whereas in 
the crisis strata, the responders would include any individual 
who had at least a 30% reduction in their domain score. The 
study might also include additional data from the two trials that 
tested rivastigmine efﬁ  cacy in dementia with Lewy body and 
galantamine efﬁ  cacy in vascular dementia. Using this meth-
odology (categorical outcome and changes in domain score) 
would enable us to report the difference in proportion of items 
improved, worsened, emerged, and/or ceased between treat-
ment and control groups, and thus, we would better understand 
the clinical meaning of positive effects. A detailed investigation 
of the effect of ChEIs on speciﬁ  c behaviors at different stages of 
illness may be beneﬁ  cial. We await the results of an acute phase 
BPSD study using memantine (MAGD ISRCTN24953404) 
and studies on new drugs such as tarenﬂ  urbil (Wilcock et al 
2008). Speciﬁ  c medical, supportive, social or psychological 
interventions in agitation require further evidence.
Conclusions
Cholinesterase inhibitors (donepezil, rivastigmine, and 
galantamine) have consistently shown a statistically 
signiﬁ  cant improvement on BPSD as measured by the NPI. 
However, the existing clinical relevance of these ﬁ  ndings is 
unclear and the use of this class of medications for BPSD does 
not appear to produce the necessary effect to be considered 
as monotherapy of behavioral or psychological symptoms 
in patients with dementia.
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